Home › Funds › PFM Health Sciences, LP › CLDX

PFM Health Sciences, LP position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

PFM Health Sciences, LP reported holding 342,751 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$12.8M, representing 1.12% of its reported portfolio and ranking #32 among its reported holdings. PFM Health Sciences, LP has disclosed CLDX holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)342.75K sh
Reported value held$12.75M
Portfolio Weight1.12%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PFM Health Sciences, LP's CLDX position evolved

PFM Health Sciences, LP first disclosed a stake in CLDX in Q4 2023 at 35,000 shares (US$1.4M). The position peaked in Q2 2026 at 342,751 shares, worth US$12.8M. Across 7 filings, PFM Health Sciences, LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 342,751 shares valued at US$12.8M — an increase of 17,794 shares quarter over quarter.. Notable position changes include a 49% increase in Q2 2024 (shares fell 8% over the following quarter), a 144% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 35.00K $1.39M New
Q1 2024 35.00K $1.47M Hold
Q2 2024 52.12K $1.93M Add
Q3 2024 52.12K $1.77M Hold
Q4 2025 133.16K $3.62M New
Q1 2026 324.96K $10.31M Add
Q2 2026 342.75K $12.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has PFM Health Sciences, LP held CLDX?

PFM Health Sciences, LP has disclosed CLDX holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

What is PFM Health Sciences, LP's current position in CLDX?

As of Q2 2026, PFM Health Sciences, LP holds 342.75K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $12.75M, representing 1.12% of its reported portfolio and ranking #32.

Has PFM Health Sciences, LP been buying or selling CLDX?

In the latest 13F filing (Q2 2026), PFM Health Sciences, LP increased its position in CLDX. The position peaked in Q2 2026 at 342.75K shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.